Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.57 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963780 | 0.88 | SCN9A (0.73) | SCN9ASCN3APARP15PARP10MAOB | |
| SCHEMBL963793 | 0.86 | SCN9A (0.78) | SCN9ACD274SCN3APARP15PARP10 | |
| SCHEMBL963824 | 0.86 | SCN9A (0.78) | SCN9ACD274SCN3APARP15PARP10 | |
| SCHEMBL964909 | 0.86 | SCN9A (0.78) | SCN9ACD274SCN3APARP15PARP10 | |
| SCHEMBL963499 | 0.84 | MAOB (0.61) | SCN9APARP10MAOB | |
| SCHEMBL966825 | 0.84 | SCN9A (0.62) | SCN9ACD274SCN3APARP15PARP10 | |
| SCHEMBL963913 | 0.83 | SCN9A (0.61) | SCN9ACD274SCN3APARP15PARP10 | |
| SCHEMBL964692 | 0.81 | SCN9A (0.67) | SCN9ACD274SCN3APARP15PARP10 | |
| SCHEMBL963826 | 0.80 | SCN3A (0.76) | SCN9ACD274SCN3APARP15PARP10 | |
| SCHEMBL6688037 | 0.79 | SCN9A (0.71) | SCN9ASCN3APARP15PARP10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | claimed |
| US-8445539-B2 | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-05-21 | — | — | US | claimed |
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-01-20 | — | — | US | claimed |
| EP-2222290-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-01 | — | — | EP | claimed |
| WO-2009080470-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-07-02 | — | — | WO | claimed |
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | disclosed |
| US-8445539-B2 | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-05-21 | — | — | US | disclosed |
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-01-20 | — | — | US | disclosed |
| EP-2222290-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009080470-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GABBR1, GABBR2, GABRA5 | SCN9A 1236/4885CD274 836/4885SCN3A 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.